TAT-10: Preclinical Evaluation of Astatinated Nanobodies for Targeted Alpha Therapy

Kanazawa, Japan (UroToday.com) This study has some similarities to the previous paper in that the nanobody (Nb) 2Rs15d-Nb is employed to target HER2+ SKOV-3 cells. The radioisotope is different with present study using the alpha-emitter At211 instead of Ac225.

To evaluate the yields, purity, and binding three different prosthetic groups were prepared with conjugates m-eATE and SGMAB for 2Rs15d-Nb and MSB for the site-specific 2Rs15d-His6-Linker-Cys. All three gave good yields and purities. The m-eATE with an activity of 118 MBq/mg gave a yield of 55% and purity 99%. The SGMA with activity 68 MBq/mg had yield 28% and purity 99%. Finally the site-specific MSB with activity 270 MBq/mg had yield 52% and purity >91%. The internalized fractions were 24.5%, 11.8%, and 25% at 1 hour and 18.1%, 10.9%, and 9.5% at 24 hours respectively for MSB, SGMAB, and me-ATE.

In vivo studies are planned to both confirm the internalization fractions and explore the biodistribution of the different At211-labeled Nb conjugates.

Presented By: Yana Dekempeneer from Laboratory of In Vivo Cellular and Molecular Imaging, Vrije Univesiiteit Brussels, Brussels, Belgium and Belgian Nuclear Research Center, Mol, Belgium

Written By: William Carithers, Lawrence Berkeley National Laboratory

at the 10th International Symposium on Targeted Alpha Therapy (TAT-10)  May 31 - June 1, 2017 - Kanazawa, Japan.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe